Compare BST & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BST | NVAX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 1995 |
| Metric | BST | NVAX |
|---|---|---|
| Price | $40.72 | $9.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | 103.1K | ★ 5.4M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 10.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.71 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $27.87 | $5.01 |
| 52 Week High | $44.50 | $10.65 |
| Indicator | BST | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 64.79 |
| Support Level | $39.80 | $7.73 |
| Resistance Level | $41.44 | $10.13 |
| Average True Range (ATR) | 0.58 | 0.61 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 49.46 | 69.08 |
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.